The results demonstrated that AZ304 inhibited cell proliferation in selected CRC cell lines, independently of BRAF mutation status, while the EGFR inhibitor Cetuximab only inhibited CRC cell lines with wild type BRAF. The gene discussed is BRAF; the disease is colorectal carcinoma.